Main Article Content
Nebivolol hydrochloride is a highly selective beta-blocker that causes vasodilation. This study addresses the use of various superdisintegrants such as Crosspovidone and croscarmellose sodium. Compounding was done using the direct compression method. Superdisintegrants are used in immediate release tablet formulations to improve disintegration and dissolution and provide a more rapid onset of action. Drug-excipient interactions were studied by FT-IR. Manufactured tablets were tested for various parameters before and after compression. Bulk density, tamped density, weight change, thickness, brittleness, disintegration time, dissolution studies, etc. Finally, it was concluded that the F-2 formulation had the highest release potential.
LPreethi et al. Formulation and evaluation of immediate release tablets of nebivolol hydrochloride, journal of global trends in pharmaceutical sciences:1790-1796
Srikant pimple et al. Formulation development and evaluation of novel combination s (-) Amlodipine and nebivolol tablets in single unit dosage: 239-243
B. Dharshini Swapna et al. Formulation and evaluation of immediate release tablet of nebivolol hydrochloride, World journal of pharmacy and pharmaceutical sciences: volume 4, issue 1, 687-698.
Rohit S Kulkarni, formulation and evaluation of immediate release tablet of Valsartan, International Journal of pharmaceutical sciences and Research, vol 6, Issue 2 :808-815
D. M Patel et al, Formulation and evaluation of Fast Dissolving Tablets of Nebivolol and Valsartan, International Journal of Pharmaceutical science and Research, vol 11, Issue11:5530-5538
Jaimini M and Rawat s: A Review on immediate Release Drug Delivery System. Research Journal of Pharmaceutical Chemical and Biological Sciences2013: 1721-1730
Ratnaparkhi M., Mohanta G. and Upadhyay L., fast dissolving tablet: A Review. International journal of pharmacy research, 2(1), 2009, 5-12.
Sekharan T.R., Kumar S and Siji R., Formulation and evaluation of mouth dissolving famotidine tablet, International journal of ChemTech Research, 1(4), 2009, 1251-1256.
Kakade S M., Mannur V.S. and Ramani K.B., formulation and evaluation of mouth dissolving tablets of losartan potassium, International journal research pharmaceutical sciences, 1(3) , 2010, 290-295.
Vimal Arora, Anil Bhandrai, Gupta V.B, Advances in Direct Compression Technology, Asian journal of pharmaceutics Vol.1 Issue 1, Oct-Dec 2006, 18-21.
Venkadalakshi R., Sasikala C. Swati R., “formulation and evaluation of Granisetron Hydrochloride immediate release Tablets”, International journal of Pharmaceutical Sciences, Sep- December 2009, Vol.1,Issue 2, 336-341.
Suresh Bandari, Rajendra Kumar Mittapalli, Ramesh Gannu “immediate release tablets An overview” , Asian journal of pharmaceutics, jan 2008, 2-11.
Shimizu T, sugaya A , Nakano Y, Izutuzu D, Mzukami Y.; formulation study for lansoprazole fast disintegrating tablets, chemical and Pharmaceutical Bulletin, 2003; 51 (10); 1121-1127.
Seong H.J Yourong F, Kinam P, Frosta; a new technology for masking fast melting tablets, Expert opinion on drug delivery,2005; 2(6) ; 1107-1116.
Raju M., Sundaramoorthy K. and Vetrichelvan T. Formulation and In-Vitro Evaluation of Sustained Release Matrix Tablets of Aceclofenac by UsingDifferent Natural Polymers, Research Journal of Pharmaceutical, Biological and Chemical Sciences., 2010, 1(4), 279-291.
Saleh M. Al-Saidan, Yellela S. R. Krishnaiah and Srinivas S. Patro. In-Vitro and InVivo Evaluation of Guar Gum Matrix Tablets for Oral Controlled Release of WaterSoluble Diltiazem Hydrochloride, AAPS Pharm. Sci. Tech., 2005, 6 (1), 1-8.
Amelia Avachat and Vikram Kotwal. Design and Evaluation of Matrix-Based Controlled Release Tablets of Diclofenac Sodium and Chondroitin Sulphate, AAPS Pharm. Sci. Tech., 2007, 8(4), 1-6.
Deepak S. and Rana A.C. Formulation Development of Quetiapine Fumarate SR Matrix Tablets, Pelagia Research Library., 2010, 1(1), 48-57.
Gohel M.C., Parikh R.K. and Padshala M.N. Formulation and Optimization of Directly Compressible Isoniazid Modified Release Matrix Tablet, Indian Journal of Pharmaceutical Sciences., 2007, 69(5), 640-645.
Aulton M.E. Pharmaceutics: The Design and Manufacture of Medicine, 3rd edn., Churchill Livingstone, New York, 2007, 355-359,483-498.
Carstensen J.T. and Rhodes C.T. Drug Stability Principles and Practices, 3rd edn., Marcel Dekker, Inc, New York, 2008, 415-481.
Goodman and Gilman‟s. The Pharmacological Basis of Therapeutics, 10th edn., Harman J.G. and Limbird L.E, New York, 2001, 1349-1359.
Manavalan R. and Ramasamy S. Physical Pharmaceutics, 2nd edn., Vignesh Publisher, Chennai, 2001, 288-299.
Patil U.K., Sourabh Jain and Yadav S.K. Preparation and Evaluation of Sustained Release Matrix Tablet of Furosemide Using Natural Polymers, Research J. Pharm. And Tech., 2008, 374-376.
Raymond C Rowe, Paul J Sheskey and Marian E Quinn. Handbook of Pharmaceutical Excipients, 6th edn., Pharmaceutical Press, London, 2009, 155, 697,772.
Skoog D.A., Holler F.J. and Crouch S.R. Fundamental of Analytical Chemistry, 8th edn., Thomson Asia Pvt. Ltd., Singapore, 2004, 775-781, 811- 819.
Willard H.H., Merritt L.L. and Settle F. A. Instrumental Methods of Analysis, 12th edn., CBS Publishers and Distributors, New Delhi, 2008, 762- 766.
Mukesh C. Gohel and Shital H.Bariya. Fabrication of Triple- Layer Matrix Tablets of Venlafaxine Hydrochloride, AAPS Pharmaceutical Sciences Technology., 2009, 10(2), 624-630.
Nikil A Karani and Prashant pingale. Analytical Method Development and Validation of Venlafaxine Hydrochloride in Solid Dosage Form using UV Spectrophotometer, Journal of Pharmacy Research., 2009, 2, 1246-1249.
Vimal D shirvi., Vijayakumar G. and channabasavaraj K.P. Third Order Derivative Spectrophotometric Estimation of Venlafaxine Hydrochloride in Bulk and Pharmaceutical Formulations, International Journal of Pharma Technology and Research., 2010, 2, 700-703.